Merus Past Earnings Performance
Past criteria checks 0/6
Merus's earnings have been declining at an average annual rate of -30.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 8.1% per year.
Key information
-30.4%
Earnings growth rate
-13.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 8.1% |
Return on equity | -43.5% |
Net Margin | -352.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Jun 04Merus EPS misses by $0.10, misses on revenue
May 06Is Merus N.V. (NASDAQ:MRUS) Popular Amongst Institutions?
Mar 08Revenue & Expenses BreakdownBeta
How Merus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 44 | -155 | 60 | 0 |
30 Sep 23 | 46 | -177 | 59 | 0 |
30 Jun 23 | 41 | -178 | 59 | 0 |
31 Mar 23 | 43 | -152 | 56 | 0 |
31 Dec 22 | 42 | -131 | 52 | 0 |
30 Sep 22 | 46 | -64 | 48 | 0 |
30 Jun 22 | 53 | -54 | 45 | 0 |
31 Mar 22 | 52 | -76 | 43 | 0 |
31 Dec 21 | 49 | -67 | 41 | 0 |
30 Sep 21 | 43 | -80 | 40 | 0 |
30 Jun 21 | 38 | -89 | 39 | 0 |
31 Mar 21 | 32 | -79 | 36 | 0 |
31 Dec 20 | 30 | -86 | 36 | 0 |
30 Sep 20 | 29 | -83 | 35 | 0 |
30 Jun 20 | 28 | -69 | 34 | 0 |
31 Mar 20 | 29 | -65 | 34 | 0 |
31 Dec 19 | 31 | -55 | 32 | 0 |
30 Sep 19 | 37 | -32 | 43 | 0 |
30 Jun 19 | 35 | -34 | 38 | 0 |
31 Mar 19 | 36 | -26 | 33 | 0 |
31 Dec 18 | 38 | -28 | 29 | 0 |
30 Sep 18 | 34 | -41 | 13 | 0 |
30 Jun 18 | 33 | -45 | 14 | 0 |
31 Mar 18 | 34 | -66 | 16 | 0 |
31 Dec 17 | 26 | -78 | 17 | 0 |
30 Sep 17 | 18 | -100 | 18 | 0 |
30 Jun 17 | 12 | -87 | 13 | 0 |
31 Mar 17 | 6 | -66 | 9 | 0 |
31 Dec 16 | 3 | -50 | 5 | 0 |
30 Sep 16 | 4 | -25 | 2 | 0 |
30 Jun 16 | 3 | -26 | 2 | 0 |
31 Mar 16 | 3 | -27 | 1 | 0 |
31 Dec 15 | 2 | -25 | 1 | 0 |
30 Sep 15 | 2 | -25 | 1 | 0 |
30 Jun 15 | 2 | -23 | -1 | 0 |
31 Mar 15 | 1 | -20 | 0 | 0 |
31 Dec 14 | 2 | -21 | 1 | 0 |
31 Dec 13 | 1 | -14 | 4 | 0 |
Quality Earnings: MRUS is currently unprofitable.
Growing Profit Margin: MRUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRUS is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare MRUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MRUS has a negative Return on Equity (-43.48%), as it is currently unprofitable.